Table 2.
Fold changes in the five most significantly detected miRNAs in the platelets from patients with Aβ(−)MCI and Aβ(+)MCI compared to those of the CNI group.
| miRNA | Aβ(−)MCI | Aβ(+)MCI | ||
|---|---|---|---|---|
| FC | p-value | FC | p-value | |
| hsa-let-7i-5p | −1.39 | 0.516 | −4.16 | 0.043 † |
| hsa-miR-125a-5p | 1.04 | 0.946 | −1.70 | 0.035 † |
| hsa-miR-1233-5p | −1.25 | 0.193 | −1.64 | 0.003 † |
| hsa-miR-6787-5p | −1.18 | 0.448 | −1.61 | 0.008 † |
| hsa-miR-6880 | 1.42 | 0.144 | 2.09 | 0.025 † |
Data are expressed as fold change (FC), and false discovery rate (FDR) was controlled by adjusting the p value using the Benjamini–Hochberg algorithm. † p < 0.05: MCI group versus CNI group. CNI, cognitive normal individual; Aβ(−)MCI, Non-Alzheimer’s pathologic change with MCI; and Aβ(+)MCI, Alzheimer’s pathologic change with MCI.